A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Relapsed B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Acute Lymphoblastic Leukemia and Lymphoma Subjects

Status Active, not recruiting

Clinical Trial Summary

This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in patients with B-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoid
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Refractory B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia
Relapsed/Refractory B-cell Lymphoma

Clinical Trial Details

NCT number	NCT03156101
Study type	Interventional
Source	Shenzhen BinDeBio Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	March 2, 2017
Completion date	December 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01860937` - T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	Phase 1
Completed	`NCT02808442` - Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia	Phase 1
Withdrawn	`NCT02167360` - Study of Efficacy and Safety of CTL019 in Adult ALL Patients	Phase 2
Recruiting	`NCT04556084` - Blinatumomab Bridging Therapy	Phase 2
Recruiting	`NCT06179524` - CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL	Phase 2
Completed	`NCT02228096` - Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients	Phase 2